Clinical trials: Keratinocyte Carcinoma, active
Non-melanoma Skin Cancer, Carcinoma, Squamous Cell
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection.
- Conditions
- Non-melanoma Skin Cancer, Carcinoma, Squamous Cell, Carcinoma, Basal Cell, Keratinocyte Carcinoma
- Trial name
- SPRINTR (NCT05955924)
- Testing
- Nicotinamide
- Where
- 7 sites in Canada
- Volunteers
- 396 people
- Sponsor
- Women's College Hospital
Basal Cell Carcinoma
Basal Cell Carcinoma Chemoprevention Trial
This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of imiquimod (IMQ) vs.
- Trial name
- B3C (NCT05212246)
- Testing
- 5% Imiquimod cream
- Where
- 8 sites in United States
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Keratinocyte Carcinoma, Basal Cell Carcinomas
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas.
- Conditions
- Keratinocyte Carcinoma, Basal Cell Carcinomas, Squamous Cell Carcinoma, Skin Cancer
- Trial name
- NCT07010692
- Testing
- Tirbanibulin ointment 1%, non-ablative fractional laser
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bruce Robinson, MD
Locally Advanced Basal Cell Carcinoma
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
- Trial name
- NCT07808515
- Testing
- Cemiplimab, Vidutolimod, Fianlimab
- Volunteers
- 135 people
- Sponsor
- Regeneron Pharmaceuticals